1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Osiris Therapeutics, Inc. - Product Pipeline Review - 2013

Osiris Therapeutics, Inc. - Product Pipeline Review - 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 27 pages

Osiris Therapeutics, Inc. - Product Pipeline Review - 2013


Summary


Global Market Direct’s pharmaceuticals report, “Osiris Therapeutics, Inc. - Product Pipeline Review - 2013” provides data on the Osiris Therapeutics, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Osiris Therapeutics, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Osiris Therapeutics, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.


Scope


- Osiris Therapeutics, Inc. - Brief Osiris Therapeutics, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Osiris Therapeutics, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Osiris Therapeutics, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Osiris Therapeutics, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.


Reasons to buy


- Evaluate Osiris Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Osiris Therapeutics, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Osiris Therapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Osiris Therapeutics, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Osiris Therapeutics, Inc. and identify potential opportunities in those areas.

Table Of Contents

Osiris Therapeutics, Inc. - Product Pipeline Review - 2013
Table of Contents 2
List of Tables 3
List of Figures 3
Osiris Therapeutics, Inc. Snapshot 4
Osiris Therapeutics, Inc. Overview 4
Key Information 4
Key Facts 4
Osiris Therapeutics, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Osiris Therapeutics, Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Osiris Therapeutics, Inc. - Pipeline Products Glance 9
Osiris Therapeutics, Inc. - Late Stage Pipeline 9
Phase III Products/Combination Treatment Modalities 9
Osiris Therapeutics, Inc. Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Phase I Products/Combination Treatment Modalities 11
Osiris Therapeutics, Inc. - Drug Profiles 12
Chondrogen 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
Osteocel-XC 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
remestemcel-L 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
Osiris Therapeutics, Inc. - Pipeline Analysis 16
Osiris Therapeutics, Inc. - Pipeline Products by Therapeutic Class 16
Osiris Therapeutics, Inc. - Pipeline Products by Route of Administration 18
Osiris Therapeutics, Inc. - Recent Pipeline Updates 19
Osiris Therapeutics, Inc. - Dormant Projects 21
Osiris Therapeutics, Inc. - Company Statement 22
Osiris Therapeutics, Inc. - Locations And Subsidiaries 25
Head Office 25
Appendix 26
Methodology 26
Coverage 26
Secondary Research 26
Primary Research 26
Expert Panel Validation 26
Contact Us 27
Disclaimer 27

List of Tables


Osiris Therapeutics, Inc., Key Information 4
Osiris Therapeutics, Inc., Key Facts 4
Osiris Therapeutics, Inc. - Pipeline by Indication, 2013 6
Osiris Therapeutics, Inc. - Pipeline by Stage of Development, 2013 7
Osiris Therapeutics, Inc. - Monotherapy Products in Pipeline, 2013 8
Osiris Therapeutics, Inc. - Phase III, 2013 9
Osiris Therapeutics, Inc. - Phase II, 2013 10
Osiris Therapeutics, Inc. - Phase I, 2013 11
Osiris Therapeutics, Inc. - Pipeline By Therapeutic Class, 2013 17
Osiris Therapeutics, Inc. - Pipeline By Route of Administration, 2013 18
Osiris Therapeutics, Inc. - Recent Pipeline Updates, 2013 19
Osiris Therapeutics, Inc. - Dormant Developmental Projects,2013 21

List of Figures


Osiris Therapeutics, Inc. - Pipeline by Indication, 2013 6
Osiris Therapeutics, Inc. - Pipeline by Stage of Development, 2013 7
Osiris Therapeutics, Inc. - Monotherapy Products in Pipeline, 2013 8
Osiris Therapeutics, Inc. - Pipeline By Therapeutic Class, 2013 16
Osiris Therapeutics, Inc. - Pipeline By Route of Administration, 2013 18

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.